

# RET, Active

Recombinant human protein expressed in Sf9 cells

## Catalog # R02-11G-10

Lot # V143-1

### **Product Description**

Recombinant human RET (658-end) was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The gene accession number is NM 020630.

### **Gene Aliases**

PTC, MTC1, HSCR1, MEN2A, MEN2B, RET51, CDHF12, RET-ELE1

#### Concentration

 $0.1 \mu g/\mu l$ 

#### **Formulation**

Recombinant protein stored in 50mM sodium phosphate, pH 7.0, 300mM NaCl, 150mM imidazole, 0.1mM PMSF, 0.25mM DTT, 25% glycerol.

## Storage, Shipping and Stability

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Stability is 1yr at -70°C from date of shipment. Product shipped on dry ice.

#### **Scientific Background**

RET gene codes for a transmembrane tyrosine kinase which is a subunit of a multimeric complex that acts as a receptor for four structurally related molecules: GDNF, neurturin, artemin and persephin (1). Germline mutations of RET cause a dominantly inherited dysgenesis of the enteric nervous system known as Hirschsprung's disease. RET is constitutively activated by point mutations in hereditary medullary thyroid carcinomas (MTCs). Several single nucleotide polymorphisms of the RET gene have been described. Multiple endocrine neoplasia type 2A (MEN 2A) have been reported to be associated with two mutations of the protooncogene RET (2).

#### References

- Geneste, O. et al: Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site. Hum Mol. Genet. 1999; 8(11):1989-99.
- Kahn, <u>Tessitore</u>, <u>A</u>. et al: A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. <u>J. Clin. Endocrinol</u>. Metab. 1999; 84(10):3522-7.

### **Purity**





Figure 1. SDS-PAGE gel image

The purity of RET was determined to be >80% by densitometry.
Approx. MW 74kDa.

## **Specific Activity**


Figure 2. Radiometric Assay Data



The specific activity of RET was determined to be **74 nmol** /min/mg as per activity assay protocol.

(For Radiometric Assay Protocol on this product please see pg. 2)

Figure 3. ADP- Glo™ Assay Data



The specific activity of RET was determined to be **220 nmol/min/mg** as per activity assay protocol.

(For ADP-Glo™ Assay Protocol on this product please see pg. 3)

# **Activity Assay Protocol**

#### **Reaction Components**

### Active Kinase (Catalog #: R02-11G-10)

Active RET  $(0.1\mu g/\mu l)$  diluted with Kinase Dilution Buffer III (Catalog #: K23-09) and assayed as outlined in sample activity plot. (Note: these are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active RET for optimal results).

### Kinase Dilution Buffer III (Catalog #: K23-09)

Kinase Assay Buffer I (Catalog #: K01-09) diluted at a 1:4 ratio (5X dilution) with 50 ng/ $\mu$ l BSA solution.

### Kinase Assay Buffer I (Catalog #: K01-09)

Buffer components: 25mM MOPS pH 7.2, 12.5mM  $\beta$ -glycerol-phosphate, 25mM MgCl<sub>2</sub>, 5mM EGTA, 2mM EDTA. Add 0.25mM DTT to Kinase Assay Buffer prior to use.

### [33P1-ATP Assav Cocktail

Prepare 250 $\mu$ M [ $^{33}$ P]-ATP Assay Cocktail in a designated radioactive working area by adding the following components: 150 $\mu$ l of 10mM ATP Stock Solution (Catalog #: A50-09), 100 $\mu$ l [ $^{33}$ P]-ATP (1mCi/100 $\mu$ l), 5.75ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 1ml aliquots at -20°C.

#### 10mM ATP Stock Solution (Catalog #: A50-09)

Prepare ATP stock solution by dissolving 55mg of ATP in 10ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 200 $\mu$ l aliquots at  $-20^{\circ}$ C.

## Substrate (Catalog #: I15-58)

IGF1Rtide synthetic peptide substrate (KKKSPGEYVNIEFG) diluted in distilled H<sub>2</sub>O to a final concentration of 1mg/ml.

#### **Assay Protocol**

- Step 1. Thaw [33P]-ATP Assay Cocktail in shielded container in a designated radioactive working area.
- Step 2. Thaw the Active RET, Kinase Assay Buffer, Substrate and Kinase Dilution Buffer on ice.
- Step 3. In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20µl:

Component 1. 10µl of diluted Active RET (Catalog #R02-11G-10)

Component 2. 5µl of 1mg/ml stock solution of substrate (Catalog #115-58)

Component 3. 5µl distilled H<sub>2</sub>O (4°C)

- **Step 4.** Set up the blank control as outlined in step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled H<sub>2</sub>O.
- Step 5. Initiate the reaction by the addition of 5 μl [33P]-ATP Assay Cocktail bringing the final volume up to 25μl and incubate the mixture in a water bath at 30°C for 15 minutes.
- **Step 6.** After the 15 minute incubation period, terminate the reaction by spotting 20 µl of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
- Step 7. Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (dilute 10ml of phosphoric acid and make a 1L solution with distilled H<sub>2</sub>O) with constant gentle stirring. It is recommended that the strips be washed a total of 3 intervals for approximately 10 minutes each.
- Step 8. Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
- **Step 9.** Determine the corrected cpm by removing the blank control value (see Step 4) for each sample and calculate the kinase specific activity as outlined below.

## Calculation of [P<sup>33</sup>]-ATP Specific Activity (SA) (cpm/pmol)

Specific activity (SA) = cpm for 5  $\mu$ l [33P]-ATP / pmoles of ATP (in 5  $\mu$ l of a 250  $\mu$ M ATP stock solution, i.e., 1250 pmoles)

### Kinase Specific Activity (SA) (pmol/min/μg or nmol/min/mg)

Corrected cpm from reaction / [(SA of  $^{33}$ P-ATP in cpm/pmol)\*(Reaction time in min)\*(Enzyme amount in  $\mu g$  or mg)]\*[(Reaction Volume)]

# **ADP-Glo™ Activity Assay Protocol**

#### **Reaction Components**

RET Kinase Enzyme System (Promega, Catalog #: V3761)

RET, Active, 10µg (0.1µg/µl)
IGF1Rtide peptide, substrate, 1ml (1mg/ml)
Reaction Buffer A (5X), 1.5ml
DTT solution (0.1M), 25µl

ADP-Glo<sup>™</sup> Kinase Assay Kit (Promega, Catalog #: V9101)

Ultra Pure ATP, 10mM (0.5ml)
ADP, 10mM (0.5ml)
ADP-Glo<sup>TM</sup> Reagent (5ml)
Kinase Detection Buffer (10ml)
Kinase Detection Substrate (Lyophilized)

#### Reaction Buffer A (5X)

200mM Tris-HCl, pH 7. 5, 100mM MgCl<sub>2</sub> and 0.5 mg/ml BSA.

#### **Assay Protocol**

The RET assay is performed using the RET Kinase Enzyme System (Promega; Catalog #: V3761) and ADP-Glo™ Kinase Assay kit (Promega; Catalog #: V9101). The RET reaction utilizes ATP and generates ADP. Then the ADP-Glo™ Reagent is added to simultaneously terminate the kinase reaction and deplete the remaining ATP. Finally, the Kinase Detection Reagent is added to convert ADP to ATP and the newly synthesized ATP is converted to light using the luciferase/luciferin reaction. For more detailed protocol regarding the ADP-Glo™ Kinase Assay, see the technical Manual #TM313, available at www.promega.com/tbs/tm313/tm313.html.

- Step 1. Thaw the ADP-Glo™ Reagents at ambient temperature. Then prepare Kinase Detection Reagent by mixing Kinase Detection Buffer with the Lyophilized Kinase Detection Substrate. Set aside.
- Step 2. Thaw the components of RET Enzyme System, ADP and ATP on ice.
- Step 3. Prepare 1ml of 2X Buffer by combining 400µl Reaction Buffer A, 1µl DTT and 599µl of dH<sub>2</sub>0.
- Step 4. Prepare 1ml of 250μM ATP Assay Solution by adding 25μl ATP solution (10mM) to 500μl of 2X Buffer and 475μl of dH<sub>2</sub>O.
- **Step 5.** Prepare diluted RET in 1X Buffer (diluted from 2X buffer) as outlined in sample activity plot. (Note: these are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active RET for optimal results).
- Step 6. In a white 96-well plate (Corning Cat # 3912), add the following reaction components bringing the initial reaction volume up to 20µl:

Component 1. 10µl of diluted Active RET

Component 2. 5µl of 1mg/ml stock solution of substrate

Component 3. 5µl of 2X Buffer

- **Step 7.** Set up the blank control as outlined in step 6, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled H<sub>2</sub>O.
- Step 8. At the same time as the RET kinase reaction, set up an ATP to ADP conversion curve at 50µM ATP/ADP range as described in the ADP-Glo™ Kinase Assay technical Manual #TM313.
- Step 9. Initiate the RET reactions by the addition of 5μl of 250μM ATP Assay Solution thereby bringing the final volume up to 25μl. Shake the plate and incubate the reaction mixture at 30°C for 15 minutes.
- Step 10. Terminate the reaction and deplete the remaining ATP by adding 25µl of ADP-Glo™ Reagent. Shake the 96-well plate and then incubate the reaction mixture for another 40 minute at ambient temperature.
- **Step 11.** Add 50µl of the Kinase Detection Reagent, shake the plate and then incubate the reaction mixture for another 30 minute at ambient temperature.
- Step 12. Read the 96-well reaction plate using the Kinase-Glo™ Luminescence Protocol on a GloMax® Microplate Luminometer (Promega; Cat # E6501).
- Step 13. Using the conversion curve, determine the amount of ADP produced (nmol) in the presence (step 6) and absence of substrate (Step 7) and calculate the kinase specific activity as outlined below. For a detailed protocol of how to determine nmols from RLUs, see ADP-Glo™ Applications Database at <a href="http://www.promega.com/applications/cellularanalysis/cellsignaling.htm">http://www.promega.com/applications/cellularanalysis/cellsignaling.htm</a>

#### Kinase Specific Activity (SA) (nmol/min/mg)

(ADP (step 6) - ADP (Step 7)) in nmol) / (Reaction time in min)\*(Enzyme amount in mg)